Thu, Dec 25, 2014, 1:53 PM EST - U.S. Markets closed for Christmas

Recent

% | $
Quotes you view appear here for quick access.

Impax Laboratories Inc. Message Board

  • shorterminator shorterminator Jan 3, 2013 2:16 PM Flag

    Will Impax sell its Global Division to Teva?

    Looking at IPXL's Global Division, IPX066 and its other product now in trials both address CNS conditions. Teva has recently announced a new strategy in which CNS is one of three focus sectors, and small to medium acquisitions will be growth drivers. Teva's CNS portfolio includes Azilect/Rasagiline, which Rytary could displace in some patients. The companies seem to know each other well - see recent CFO appointment. IPXL's revenue comes overwhelmingly from the generics division. Are branded products really a strategic priority for the company? Or could they be interested in selling them off (after FDA approval) to reinvest in generics? Not pumping - just curious if any one out there has an opinion.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
IPXL
31.32+0.26(+0.84%)Dec 24 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Yahoo! Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Noble Energy, Inc.
NYSEWed, Dec 24, 2014 2:48 PM EST